Slave1,
This is not very obvious especially for me. I thought originally the automatic device Eden was designed for DCvax-L to mimic how the artisan method was done.
I read somewhere Mimicking the artisan method is key so the device should produce almost the same result or biosimilar.
It is very lengthy and time consuming process I believe because mimicking something out of certain artisan methods is very hard. Therefore they had spent many years trying to get the best outcome.
But after reading your post, I learned something new today. You could be right. I also like to believe if the version of Eden device today is much more advanced and powerful than the version two years ago. I’d like to see the efforts are successful so that manufacture hyperactive DCs can be accomplished via this device. That would be good preparation before starting the next DCvax-Direct trials. Years of struggling to develop something good and useful finally yielding great results.
Yes, I would love to see this new Direct trial to use the greatest and latest version of Eden. If that happens, lessons learned from DCvax-L trials implemented to Direct trials. So when regulators let’s say ready to approve Direct because the tumors were melted by the hyperactive DC, the manufacturing is ready without any further delay. All IMO.
AI
Market Data 
Markets 
